Outcomes associated with initial versus later vancomycin use in patients with complicated skin and skin-structure infections

PharmacoEconomics

Volumn 27, Issue 5, 2009, Pages 421-430

  Itani, Kamal M F ^a,c   Akhras, Kasem S ^b   Stellhorn, Robert ^b   Quintana, Alvaro ^b   Budd, David ^b   Merchant, Sanjay ^b  

^a BOSTON UNIVERSITY   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^c VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; VANCOMYCIN;

ADULT; ARTICLE; DATA BASE; ECONOMIC EVALUATION; FEMALE; HOSPITAL ADMISSION; HOSPITAL COST; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; MORTALITY; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN INFECTION; SOFT TISSUE INFECTION; STATISTICAL ANALYSIS; STATISTICAL MODEL; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; COHORT STUDIES; DATABASES AS TOPIC; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; RETREATMENT; SKIN DISEASES, BACTERIAL; STAPHYLOCOCCAL SKIN INFECTIONS; TIME FACTORS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 67849093862     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/00019053-200927050-00006     Document Type: Article

References (22)

1. Lee SY, Kuti JL, Nicolau DP. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg Infect (Larchmt) 2005; 6 (3): 283-95
2. Moet GJ, Jones RN, Biedenbach DJ, et al. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn Microbiol Infect Dis 2007; 57 (1): 7-13. Epub 2006 Oct 23
3. Frazee BW, Lynn J, Charlebois ED, et al. High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections. Ann Emerg Med 2005; 45 (3): 311-20
4. Jones ME, Karlowsky JA, Draghi DC, et al. Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. Int J Antimicrob Agents 2003; 22 (4): 406-19
5. Tiemersma EW, Bronzwaer SL, Lyytikainen O, et al. Methicillin-resistant Staphylococcus aureus in Europe, 1999-2002. Emerg Infect Dis 2004; 10 (9): 1627-34
6. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005; 352 (14): 1436-44
7. Lodise Jr TP, McKinnon PS. Burden of methicillin-resistant Staphylococcus aureus: focus on clinical and economic outcomes. Pharmacotherapy 2007; 27 (7): 1001-12
8. Evans ME, Kortas KJ. Vancomycin use in a university medical center: comparison with hospital infection control practices advisory committee guidelines. Infect Control Hosp Epidemiol 1996; 17 (6): 356-9
9. Hamilton-Miller JM. Vancomycin-resistant Staphylococcus aureus: a real and present danger? Infection 2002; 30 (3): 118-24
10. Cosgrove SE, Qi Y, Kaye KS, et al. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005; 26 (2): 166-74
11. Fraser A, Paul M, Almanasreh N, etal. Benefit of appropriate empirical antibiotic treatment: thirty-day mortality and duration of hospital stay. Am J Med 2006; 119 (11): 970-6
12. Frei CR, Restrepo MI, Mortensen EM, et al. Impact of guideline-concordant empiric antibiotic therapy in community-acquired pneumonia. Am J Med 2006; 119 (10): 865-71
13. Iregui M, Ward S, Sherman G, et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002; 122 (1): 262-8
14. Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis 2005; 52 (2): 113-22
15. Premier, Inc. [online]. Available from URL: http://www. premierinc.com/index.jsp [Accessed 2008 Feb 13]
16. Shah NP, Reddy P, Paladino JA, et al. Direct medical costs associated with using vancomycin in methicillin-resistant Staphylococcus aureus infections: an economic model. Curr Med Res Opin 2004; 20 (6): 779-90
17. Gemmell CG, Edwards DI, Fraise AP, et al. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 2006; 57 (4): 589-608
18. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and softtissue infections. Clin Infect Dis 2005; 41 (10): 1373-406
19. Graffunder EM, Venezia RA. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother 2002; 49 (6): 999-1005
20. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355 (7): 666-74
21. Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124 (5): 1789-97
22. Das I, O'Connell N, Lambert P. Epidemiology, clinical and laboratory characteristics of Staphylococcus aureus bacteraemia in a university hospital in UK. J Hosp Infect 2007; 65 (2): 117-23